Violations Uncovered At GSK, Pfizer Chinese Plants
This article was originally published in PharmAsia News
Executive Summary
Both GSK and Pfizer recently have to face challenges from regulatory authorities back home for problems discovered at their manufacturing facilities in China. The two companies said they took the issues seriously working on resolving them.